Potential for clinical applications using human peripheral blood-derived iHep cells
| Project/Area Number |
18K18369
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 90110:Biomedical engineering-related
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
Udono Miyako 九州大学, 農学研究院, 学術研究員 (30815543)
|
|---|
| Project Period (FY) |
2018-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | iHep細胞 / ダイレクトリプログラミング / 血液 / T細胞 / 末梢血 / H-iHep細胞 |
|---|
| Outline of Final Research Achievements |
In this study, we aimed to generate human hepatocyte progenitor cells with high proliferative and differentiation potential by direct reprogramming. After re-examining the combination of transcription factors important for liver development, we finally succeeded in generating human iHep cells capable of stable proliferation in long-term culture by introducing three transcription factors (FOXA3, HNF1A, and HNF6) into vascular endothelial cells derived from human umbilical veins and peripheral blood. These cells were found to have the ability to form liver and bile duct tissue-like structures in 3D culture and to differentiate and mature into functional hepatocytes and bile duct epithelial cells, respectively.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究によって開発された方法を用いることで、機能的に成熟した肝細胞や胆管上皮細胞をヒトiHep細胞から大量に増やし臨床での使用および凍結保存が可能になると考えられる。将来的には、肝臓から採取される肝細胞や胆管上皮細胞の代わりにヒトiHep細胞由来の肝細胞・胆管上皮細胞を用いることで、重篤な肝疾患患者に対する新しい移植医療の実現や、個人に応じた薬剤スクリーニングや毒性を評価できるシステムの構築が期待される。
|
Report
(2 results)
Research Products
(3 results)
